365 related articles for article (PubMed ID: 31009836)
21. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
22. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
23. [Reversing multidrug resistance of epidermoid carcinoma drug-resistant cell line KB-MRP1 by tetrandrine].
Chen XS; Bao MH; Mei XD
Ai Zheng; 2007 Aug; 26(8):846-50. PubMed ID: 17697545
[TBL] [Abstract][Full Text] [Related]
24. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene.
Xu HB; Li L; Fu J; Mao XP; Xu LZ
Pharmacology; 2012; 89(5-6):303-12. PubMed ID: 22573000
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
26. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression.
Pan J; Miao D; Chen L
Chem Biol Interact; 2018 May; 288():32-37. PubMed ID: 29655913
[TBL] [Abstract][Full Text] [Related]
27. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
28. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway.
Lin KN; Jiang YL; Zhang SG; Huang SY; Li H
Biomed Pharmacother; 2020 May; 125():109885. PubMed ID: 32007917
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
30. Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1).
Matsunaga S; Asano T; Tsutsuda-Asano A; Fukunaga Y
Cancer Chemother Pharmacol; 2006 Sep; 58(3):348-53. PubMed ID: 16331495
[TBL] [Abstract][Full Text] [Related]
31. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
32. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
33. Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells.
Chaisit T; Siripong P; Jianmongkol S
Eur J Pharmacol; 2017 Jan; 795():50-57. PubMed ID: 27916559
[TBL] [Abstract][Full Text] [Related]
34. Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
Chauvier D; Morjani H; Manfait M
Breast Cancer Res Treat; 2002 May; 73(2):113-25. PubMed ID: 12088114
[TBL] [Abstract][Full Text] [Related]
35. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
36. Reversal effect of vitamin D on different multidrug-resistant cells.
Yan M; Nuriding H
Genet Mol Res; 2014 Aug; 13(3):6239-47. PubMed ID: 25158250
[TBL] [Abstract][Full Text] [Related]
37. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Sampson A; Peterson BG; Tan KW; Iram SH
Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.
Shinoda C; Maruyama M; Fujishita T; Dohkan J; Oda H; Shinoda K; Yamada T; Miyabayashi K; Hayashi R; Kawagishi Y; Fujita T; Matsui S; Sugiyama E; Muraguchi A; Kobayashi M
Int J Cancer; 2005 Oct; 117(1):21-31. PubMed ID: 15880572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
